Patients with Enteropathy-Associated T-Cell Lymphoma in the United States From 2000 to 2018: SEER data-base analysis.

Ahmed K. Awad,Rehmat Ullah Awan,Ayman K. Awad,Ambreen Nabeel,Sophia Dar,Ayokunle Abegunde

DOI: https://doi.org/10.1016/j.ctarc.2023.100745

2023-07-22

Cancer Treatment and Research Communications

Abstract:Background Enteropathy-Associated T-Cell Lymphoma (EATL) is a rare lymphoma of T-cell origin associated with celiac disease. There is limited evidence in the literature about the incidence and causes of death in patients with EATL. Methods We performed a retrospective study through analyzing the Surveillance, Epidemiology, and End Results (SEER) data base to determine the incidence, trends and causes of death of patients with EATL in the U.S from 2000 to 2018. Baseline characteristics with treatment options (surgery, radiotherapy, and chemotherapy), status of patients either alive, dead due to cancer itself or other non-cancerous causes with listing of those non-cancerous causes was retrieved. Sub-group analysis based on sex was also done. Multiple latency periods (<2 year, 2-5, 6–10, 11-15, and more than 15 years) were analyzed following EATL diagnosis. Results There were 259 EATL patients, majority were aged 70-74 years old (n=36, 13.9%), predominantly males 155 (59.8%), most common in whites, (76.4%, n= 198), EATL was the only primary tumor in 177 (68.3%) cases, most common site was small bowel at different sites 84 (32.4%) followed by jejunum specifically 57 (22%), majority went for surgical resection (69.9%, n= 181) followed by chemotherapy (47.5%, n=123), 217 (83.7%) died during follow-up in this study, Conclusion EATL is a rare entity, mostly seen in males, between 70-74 years, and mostly originated in the small bowel. With over 80% death in five-year follow up period, EATL patients showed better survival if they underwent chemotherapy. More studies are needed for further understanding of this rare entity. Micro With the limited evidence in the literature about the incidence and causes of death in patients with Enteropathy-Associated T-Cell Lymphoma (EATL), we analyzed the Surveillance, Epidemiology, and End Results (SEER) data base to determine the incidence, trends and causes of death of patients with EATL in the U.S from 2000 to 2018. Baseline characteristics were extracted. Moreover, treatment options (surgery, radiotherapy, and chemotherapy), status of patients either alive, dead due to cancer itself or other non-cancerous causes with listing of those non-cancerous causes was retrieved. Sub-group analysis based on sex was also done. Multiple latency periods (<2 year, 2-5, 6–10, 11-15, and more than 15 years) were analyzed following EATL diagnosis. 259 EATL patients were identified, majority were aged 70-74 years old (n=36, 13.9%), predominantly males 155 (59.8%), most common in whites, (76.4%, n= 198), EATL was the only primary tumor in 177 (68.3%) cases, most common site was small bowel at different sites 84 (32.4%) followed by jejunum specifically 57 (22%), majority went for surgical resection (69.9%, n= 181) followed by chemotherapy (47.5%, n=123), 217 (83.7%) died during follow-up in this study. Therefore, EATL is a rare entity, mostly seen in males, between 70-74 years, and mostly originated in the small bowel. With over 80% death in five-year follow up period, EATL patients showed better survival if they underwent chemotherapy. More studies are needed for further understanding of this rare entity.